FIELD: biotechnology.
SUBSTANCE: invention relates to an mRNA sequence containing a coding region which codes a respiratory syncytial virus (RSV) mutant protein, and can be used in medicine.
EFFECT: described invention can be used to produce a pharmaceutical composition, primarily a vaccine, for preventing or treating RSV infections caused by a respiratory syncytial virus.
26 cl, 17 dwg, 7 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RABIES VACCINE | 2014 |
|
RU2712743C2 |
| VACCINE BASED ON AAV5 FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-CoV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2020 |
|
RU2783313C1 |
| VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY TO THE SARS-CoV-2 VIRUS AND/OR THE PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2761879C1 |
| AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-COV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-COV-2 | 2020 |
|
RU2760301C1 |
| MESSENGER RNA VACCINES AGAINST WIDE RANGE OF CORONAVIRUS VARIANTS | 2022 |
|
RU2826172C2 |
| ARTIFICIAL GENES CODING EV.CTL AND EV.Th PROTEINS-IMMUNOGENS, RECOMBINANT PLASMID DNA pEV.CTL AND EV.Th, PROVIDING EXPRESSION OF ARTIFICIAL GENES, AND ARTIFICIAL T-CELL POLYEPITOPE PROTEINS-IMMUNOGENS EV.CTL AND EV.Th CONTAINING EPITOPES OF EBOLA VIRUS ANTIGENS, USED TO CREATE AN EBOLA VIRUS VACCINE | 2018 |
|
RU2713723C1 |
| IMMUNOGLOBULIN WITH ONE VARIABLE DOMAIN AGAINST RSV F-PROTEIN | 2016 |
|
RU2730671C2 |
| VACCINES BASED ON VIRUS-LIKE PARTICLES (VLP) OF CANINE PARVOVIRUS (CPV) AND APPLICATION THEREOF | 2016 |
|
RU2710854C1 |
| FMDV RECOMBINANT VACCINES AND USE THEREOF | 2015 |
|
RU2745373C2 |
| NOVEL EUKARYOTIC CELLS AND METHODS FOR PREPARING THEM FOR RECOMBINANT EXPRESSION OF A PRODUCT OF INTEREST | 2014 |
|
RU2720525C2 |
